• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cardiol Young . Short to midterm follow-up of multi-system inflammatory syndrome in children with special reference to cardiac involvement

tetano

Editor, Senior Moderator
Cardiol Young


. 2022 Mar 24;1-9.
doi: 10.1017/S1047951122000828. Online ahead of print.
Short to midterm follow-up of multi-system inflammatory syndrome in children with special reference to cardiac involvement


Omeir A Aziz[SUP] 1 [/SUP], Masood Sadiq[SUP] 1 [/SUP], Ahmad U Qureshi[SUP] 1 [/SUP], Najam Hyder[SUP] 1 [/SUP], Uzma Kazmi[SUP] 1 [/SUP], Afsheen Batool[SUP] 2 [/SUP], Samia Naz[SUP] 2 [/SUP], Asma Mushtaq[SUP] 2 [/SUP], Attia Bari[SUP] 2 [/SUP], Junaid Rashid[SUP] 2 [/SUP]



Affiliations

Abstract

Objectives: We aim to describe the early and upto 16 months follow-up of post-coronavirus disease (COVID), multi-system inflammatory syndrome in children (MIS-C), with special reference to cardiac involvement.
Study design: This cohort non-interventional descriptive study included patients <18 years admitted between May, 2020 and April, 2021. Based on underlying similarities, children were classified as post-COVID MIS-C with overlapping Kawasaki Disease, MIS-C with no overlapping Kawasaki Disease, and MIS-C with shock. Post-discharge, patients were followed at 1, 3, 6, 12, and 16 months.
Results: Forty-one patients predominantly males (73%), at median age of 7 years (range 0.2-16 years) fulfilled the World Health Organisation criteria for MIS-C. Cardiac involvement was seen in 15 (36.5%); impaired left ventricle (LV) function in 5 (12.2%), coronary artery involvement in 10 (24.4%), pericardial effusion in 6 (14.6%) patients, and no arrhythmias. There were two hospital deaths (4.9%), both in MIS-C shock subgroup (2/10, 20%). At 1 month, there was persistent LV dysfunction in 2/5, coronary artery abnormalities in 7/10, and pericardial effusion resolved completely in all patients. By 6 months, LV function returned to normal in all but coronary abnormalities persisted in two patients. At last follow-up (median 9.8 months, interquartile range 2-16 months), in 36/38 (94.7%) patients, coronary artery dilatation was persistent in 2 (20%) patients.
Conclusions: Children with MIS-C have a good early outcome, though MIS-C with shock can be life-threatening subgroup in a resource-constrained country setting. On midterm follow-up, there is normalisation of LV function in all and recovery of coronary abnormalities in 80% of patients.

Keywords: COVID-19; Multi-system inflammatory syndrome in children; SARS-CoV-2; coronary artery aneurysms.
 
Back
Top Bottom